Evidence-based due – an integrative benefit-risk decision making on proton pump inhibitors

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: HSIEH, Hui-Hsia (Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Pharmacy, Taichung, China Taiwan)
  • Co-author(s): Hui-Hsia Hsieh:
    Tien-Yuan Wu: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China;Pharmacology, Tzu Chi University, Hualien, Taiwan, Province of China
    Hsun-Yang Chuang: Research, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
    Chi-Hua Chen: Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, Province of China
    Mann-Jen Hour: Pharmacy, China Medical University, Taichung, Taiwan, Province of China
  • Abstract:

    Background

    The American College of Gastroenterology recommendations that high-dose continuous infusion of proton pump inhibitors (PPIs) should be given to the high-risk bleeding ulcer patients after endoscopic management. The other meta-analysis studies showed that non-high dose intermittent PPI therapy is not inferior to high-dose continuous..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login